Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease

KIREL, BIRGÜL; Ulualan, Gökçen; Küskü kiraz, Zeynep

doi:10.24953/turkjped.2020.3003

Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease

Gökçen ULUALAN, (Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Eskişehir, Türkiye)

Zeynep Kuşku KİRAZ, (Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Eskişehir, Türkiye)

Birgül KIREL (Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Çocuk Endokrinoloji Anabilim Dalı, Eskişehir, Türkiye)

Turkish Journal of Pediatrics

2 1

Yıl: 2022 Cilt: 64 Sayı: 2 Sayfa Aralığı: 246 - 254 Metin Dili: İngilizce DOI: 10.24953/turkjped.2020.3003 İndeks Tarihi: 15-12-2022

Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease

Öz:

Background. Irisin is a newly defined myokine which is induced by exercise, which stimulates white fat cells to have the characteristics of brown adipose tissue cell. It thereby causes thermogenesis, energy and weight loss and improvement in insulin sensitivity. These effects of irisin suggest that it may be associated with obesity, insulin resistance and non-alcoholic fatty liver disease (NAFLD). Methods. The aim of the present study was to determine the relationship of serum irisin levels in obese children with NAFLD. A total of 60 pubertal obese adolescents (age range: 11-18 yrs) as well as age and sex matched 28 healthy children were included in the study. Thirty of obese patients had NAFLD. Results. The median irisin levels were lower in the obese patients both with and without NAFLD when compared with the control group. NAFLD group had a higher BMI than obese controls, however, the irisin levels were not different between these groups. The irisin levels were negatively correlated with BMI, BMI SDS, waist, hip and arm circumferences, waist/hip ratio, triceps-biceps skinfold thickness and AST, ALT levels in the all study groups. However, it was positively correlated with BMI, BMI SDS and waist and hip circumference in the entire obese group and positively with BMI SDS in the NAFLD subgroup. Conclusions. Consequently, circulating irisin levels are lower in obese adolescents and negatively correlated with body adiposity. In NAFLD patients, it may be related to steatosis and may decrease with liver damage.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Boström P, Wu J, Jedrychowski MP, et al. A PGC1- α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468. https://doi.org/10.1038/ nature10777
2. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009; 360: 1518-1525. https://doi.org/10.1056/ NEJMoa0808949
3. Gonzalez-Gil AM, Peschard-Franco M, Castillo EC, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome. Diabetal Metab Syndr 2019; 11: 63. https://doi.org/10.1186/s13098-019-0458-2
4. Shim YS, Kang MJ, Yang S, Hwang IT. Irisin is a biomarker for metabolic syndrome in prepubertal children. Endocr J 2018; 65: 23-31. https://doi. org/10.1507/endocrj.EJ17-0260
5. Binay Ç, Paketçi C, Güzel S, Samancı N. Serum irisin and oxytocin levels as predictors of metabolic parameters in obese children. J Clin Res Pediatr Endocrinol 2017; 9: 124-131. https://doi.org/10.4274/ jcrpe.3963
6. Palacios-González B, Vadillo-Ortega F, Polo-Oteyza E, et al. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin. Obesity (Silver Spring) 2015; 23: 729-732. https://doi.org/10.1002/oby.21029
7. Jang HB, Kim HJ, Kang JH, Park SI, Park KH, Lee HJ. Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents. Metabolism 2017; 73: 100-108. https:// doi.org/10.1016/j.metabol.2017.05.007
8. Reinehr T, Elfers C, Lass N, Roth CL. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. J Clin Endocrinol Metab 2015; 100: 2123-2130. https://doi.org/10.1210/ jc.2015-1208
9. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778. https://doi.org/10.1210/jc.2012-2749
10. Elizondo-Montemayor L, Silva-Platas C, Torres- Quintanilla A, et al. Association of irisin plasma levels with anthropometric parameters in children with underweight, normal weight, overweight, and obesity. Biomed Res Int 2017; 2017: 2628968. https:// doi.org/10.1155/2017/2628968
11. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides 2013; 39: 125-130. https://doi.org/10.1016/j. peptides.2012.11.014
12. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738. https://doi.org/10.1016/j. metabol.2012.09.002
13. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907. https://doi.org/10.1210/jc.2013- 2373
14. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One 2014; 9: e94235. https://doi. org/10.1371/journal.pone.0094235
15. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101. https://doi.org/10.1016/j. diabres.2013.01.007
16. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365-369. https:// doi.org/10.1016/j.jdiacomp.2013.03.002
17. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014; 63: 207-217. https://doi.org/10.1016/j. metabol.2013.09.013
18. Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013; 59: 557-562. https://doi. org/10.1016/j.jhep.2013.04.030
19. Choi ES, Kim MK, Song MK, et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014; 9: e110680. https://doi.org/10.1371/journal. pone.0110680
20. Shanaki M, Moradi N, Emamgholipour S, et al. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr 2017; 11: S467-S472. https:// doi.org/10.1016/j.dsx.2017.03.037
21. Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenteral Hepatol 2019; 16: 517- 530. https://doi.org/10.1038/s41575-019-0169-z
22. Petta S, Valenti L, Marra F, et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease. J Hepatol 2016; 64: 682- 690. https://doi.org/10.1016/j.jhep.2015.10.016
23. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012; 1821: 809-818. https://doi. org/10.1016/j.bbalip.2011.10.016
24. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67: 829-846. https://doi. org/10.1016/j.jhep.2017.05.016
25. Arias-Loste MT, Ranchal I, Romero-Gómez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci 2014; 15: 23163-23178. https://doi.org/10.3390/ ijms151223163
26. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283. https://doi.org/10.1136/gut.2011.242073
27. Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul) 2018; 33: 33-43. https://doi.org/10.3803/ EnM.2018.33.1.33
28. Hu J, Ke Y, Wu F, et al. Circulating ırisin levels in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenteral Res Pract 2020; 2020: 881891. https://doi. org/10.1155/2020/8818191
29. Rizk FH, Elshweikh SA, Abd El-Naby AY. Irisin levels in relation to metabolic and liver functions in Egyptian patients with metabolic syndrome. Can J Physiol Pharmacol 2016; 94: 359-362. https://doi. org/10.1139/cjpp-2015-0371
30. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303. https://doi.org/10.1136/adc.44.235.291
31. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23. https://doi.org/10.1136/adc.45.239.13
32. Neyzi O, Furman A, Bundak R, Gunoz H, Darendeliler F, Bas F. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr 2006; 95: 1635-1641. https://doi.org/10.1080/08035250600652013
33. Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu M, Kendirici M, Keskin M, Kondolot M. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol 2010; 2: 100-106. https://doi. org/10.4274/jcrpe.v2i3.100
34. Kim SH, Lee JM, Kim JH, et al. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images-initial experience. Radiology 2005; 234: 793- 803. https://doi.org/10.1148/radiol.2343040142
35. Pardo M, Crujeiras AB, Amil M, et al. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014; 2014: 857270. https:// doi.org/10.1155/2014/857270
36. Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/ irisin is not only a myokine but also an adipokine. PLoS One 2013; 8: e60563. https://doi.org/10.1371/ journal.pone.0060563
37. Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014; 592: 1091-1107. https://doi. org/10.1113/jphysiol.2013.264655
38. Crujeiras AB, Zulet MA, Lopez-Legarrea P, et al. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism 2014; 63: 520- 531. https://doi.org/10.1016/j.metabol.2013.12.007
39. Leung PS. The potential of irisin as a therapeutic for diabetes. Future Med Chem 2017; 9: 529-532. https:// doi.org/10.4155/fmc-2017-0035

APA	Ulualan G, Küskü kiraz Z, KIREL B (2022). Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. , 246 - 254. 10.24953/turkjped.2020.3003
Chicago	Ulualan Gökçen,Küskü kiraz Zeynep,KIREL BIRGÜL Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. (2022): 246 - 254. 10.24953/turkjped.2020.3003
MLA	Ulualan Gökçen,Küskü kiraz Zeynep,KIREL BIRGÜL Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. , 2022, ss.246 - 254. 10.24953/turkjped.2020.3003
AMA	Ulualan G,Küskü kiraz Z,KIREL B Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. . 2022; 246 - 254. 10.24953/turkjped.2020.3003
Vancouver	Ulualan G,Küskü kiraz Z,KIREL B Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. . 2022; 246 - 254. 10.24953/turkjped.2020.3003
IEEE	Ulualan G,Küskü kiraz Z,KIREL B "Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease." , ss.246 - 254, 2022. 10.24953/turkjped.2020.3003
ISNAD	Ulualan, Gökçen vd. "Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease". (2022), 246-254. https://doi.org/10.24953/turkjped.2020.3003

APA	Ulualan G, Küskü kiraz Z, KIREL B (2022). Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics, 64(2), 246 - 254. 10.24953/turkjped.2020.3003
Chicago	Ulualan Gökçen,Küskü kiraz Zeynep,KIREL BIRGÜL Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics 64, no.2 (2022): 246 - 254. 10.24953/turkjped.2020.3003
MLA	Ulualan Gökçen,Küskü kiraz Zeynep,KIREL BIRGÜL Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics, vol.64, no.2, 2022, ss.246 - 254. 10.24953/turkjped.2020.3003
AMA	Ulualan G,Küskü kiraz Z,KIREL B Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics. 2022; 64(2): 246 - 254. 10.24953/turkjped.2020.3003
Vancouver	Ulualan G,Küskü kiraz Z,KIREL B Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics. 2022; 64(2): 246 - 254. 10.24953/turkjped.2020.3003
IEEE	Ulualan G,Küskü kiraz Z,KIREL B "Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease." Turkish Journal of Pediatrics, 64, ss.246 - 254, 2022. 10.24953/turkjped.2020.3003
ISNAD	Ulualan, Gökçen vd. "Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease". Turkish Journal of Pediatrics 64/2 (2022), 246-254. https://doi.org/10.24953/turkjped.2020.3003